Novo-Nordisk A/S (NVO) — 分析摘要
Novo-Nordisk A/S（NVO）的市值为192.00十亿美元，最近一年的营收同比增长了+11.3%。净利润率为33.1%。当前市盈率为12.4倍。
核心要点
- 营收同比变化+11.3%
- 净利润率33.1%
- 市盈率12.4倍
NVO的营收增长为+11.3%，市盈率为12.4倍。
Novo-Nordisk A/S (NVO)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
流动比率为 0.80x — 流动负债超过流动资产
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
员工人数
69,500
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$1.16
股息收益率
2.67%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。